1. Generics Bulletin
  2. >>Products

‘Speculation Is Not Science’: Lupin Breezes Past Galderma On US Oracea Patents

Indian Firm Faces Immediate Appeal, After Originator Slammed By US District Court

 
• By Dean Rudge

Lupin received a more than favorable backing from a US district judge in Delaware, as the court shot down Galderma’s arguments that the Indian firm’s ANDA product would infringe two of its US Oracea patents.

Victory
• Source: Shutterstock

A US district court in Delaware has scolded Galderma, telling the firm that it had “a theory but no proof,” as it firmly rejected the originator’s infringement claim against Lupin over two US patents shielding the Oracea (doxycycline) modified-release capsule treatment for rosacea.

In response, Galderma has filed an immediate appeal to the US Court of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.